Онкогематология (Nov 2022)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review

  • N. V. Stepanova,
  • E. R. Machulaitene,
  • G. N. Salogub,
  • E. V. Melnikova

DOI
https://doi.org/10.17650/1818-8346-2009-0-1-21-28
Journal volume & issue
Vol. 0, no. 1
pp. 21 – 28

Abstract

Read online

Peripheral neuropathy is one of the most common complications of Bortezomib treatment. In this article you can find a brief literature review and single center experience: we estimated the prevalence of neuropathy development and it’s characteristics in a group of 33 patients. Peripheral neuropathy was found in 16 (48.5%) patients. In this group initial manifestations of neurotoxicity (grade I and II) were found in 8 (50%) patients. Advanced neuropathy (grade III and IV) was found in 6 (37.5%) and 2 (12.5%) patients respectively. In the majority of patients neuropathy was reversible if Bortezomibe dose was modified and symptomatic treatment was administered at the proper time.

Keywords